Document:

exv10w22

 

EXHIBIT-10.22

Execution Copy

SETTLEMENT AGREEMENT

     THIS SETTLEMENT AGREEMENT (this “Agreement”) is made and entered into as of the 29th day of
March, 2007 (the “Effective Date”) by and among Palomar Medical Technologies, Inc., a
Delaware corporation, with offices at 82 Cambridge Street, Burlington, MA 01803
(“Palomar”), The General Hospital Corporation, a Massachusetts corporation with offices at
Fruit Street, Boston MA 02114 (“General”), and Alma Lasers, Inc., a Delaware corporation
with offices at 485 Half Day Road #100, Buffalo Grove, IL 60089 (“Alma”). Each of Palomar, General,
and Alma is a “Party” and together they are the “Parties” hereunder.

     WHEREAS, Palomar, General and Alma are parties to a lawsuit captioned: (i) “Palomar Medical
Technologies, Inc. v. Alma Lasers, Inc.” Case No. 1:06-CV-11171, which is currently pending in the
United States District Court for the District of Massachusetts (the ”Lawsuit”);

     WHEREAS, the Lawsuit generally concerns allegations of infringement and invalidity of the
Anderson Patents; and

     WHEREAS, Palomar and General on the one hand and Alma on the other hand wish to settle and
compromise the Lawsuit on the terms and conditions set forth below;

     NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the
Parties covenant and agree as follows:

     1. The Closing. A closing (the “Closing”) of the transactions contemplated
hereby shall be held simultaneously with the execution and delivery of this Agreement. At the
Closing and in partial consideration of the payment made by Alma pursuant to Section 3(a), the
following actions shall take place:

          (a) Alma and Alma Lasers, Ltd. on the one hand and Palomar on the other hand shall execute and
deliver to each other the “Patent License Agreement” in the form attached hereto as
Exhibit A;

          (b) Alma and Alma Lasers, Ltd. on the one hand and Palomar on the other hand shall execute and
deliver to each other the Trade Dress Settlement Agreement (“TDS
Agreement”) in the form attached hereto as Exhibit B;

          (c) Each of the Parties shall deliver to the other Parties executed “Consent
Judgment” described in Section 2, in the form attached hereto as Exhibit C; and

          (d) Each of the Parties shall deliver to the other Parties executed “Stipulated Dismissal
With Prejudice” described in Section 2, in the form attached hereto as Exhibit D.

     2. Termination of the Lawsuit. The Parties shall execute, or cause their attorneys of
record in the Lawsuit to execute, the Consent Judgment, a copy of which have been provided to the
Parties and to their respective counsel. Within two (2) business days of Alma’s payment in full to
Palomar of the aggregate amount due pursuant to Section 3(a) of this Agreement, the aggregate
amount due pursuant to Section 4.2 of the Patent License Agreement and the aggregate amount due
pursuant to Section 4(a) of the TDS Agreement, Palomar’s counsel shall file such

 

 

Settlement Agreement

executed Consent Judgment with the District of Massachusetts. Upon the entry of the Consent
Judgment by the court, but not before, Palomar’s counsel shall file such executed Stipulated
Dismissal With Prejudice with the District of Massachusetts. No other Party or their counsel shall
file the Consent Judgment or the Stipulation of Dismissal With Prejudice with any court. The
Parties shall perform all acts necessary to facilitate each appropriate court’s prompt approval and
entry of the Consent Judgment and Stipulated Dismissal With Prejudice as orders of such court,
including executing and filing with such court any other appropriate documents. If for any reason
an appropriate court does not approve the Consent Judgment and Stipulated Dismissal With Prejudice
and enter the same as orders of such court, the Parties shall promptly confer in good faith to use
commercially reasonable efforts to modify the same or take such other actions as are required to
overcome such court’s objections and effectuate such dismissal. The entry of the Consent Judgment
and Stipulated Dismissal With Prejudice as orders of the respective courts is an express condition
to the effectiveness of this Agreement, the Patent License Agreement and the TDS Agreement,
provided that, for clarity, Alma shall pay such two aggregate amounts before Palomar’s counsel
files the Consent Judgment.

     3. Legal Costs and Expenses. 

          (a) As partial consideration hereunder, Alma shall pay to Palomar within seven (7) days of the
Effective Date (exclusive of any amounts due under the Patent License Agreement and TDS Agreement)
an amount equal to Two Hundred Seventy Five Thousand Dollars (U.S. $275,000) to cover Palomar’s
legal costs and expenses related to the Lawsuit. The payment contemplated by this Section 3(a)
shall be made by wire transfer, without deduction for any taxes or other charges, in U.S. dollars
to the credit of:

          Palomar’s account:

Bank Name: Banknorth

Bank Address: 370 Main Street
                         Worcester, MA 01608

Palomar Medical Technologies, Inc.

Account No. 8241022982

ABA No. 211370545

          (b) Patent
License Agreement and TDS Agreement. As partial consideration for their mutual
obligations hereunder, Palomar and Alma (together with Alma Lasers, Ltd.) have executed the Patent
License Agreement and TDS Agreement.

     4. Releases and Indemnities. 

          (a) Release of Palomar and General by Alma.

               (i) Of Palomar. Each of Alma and all Alma Affiliates, together with (as applicable) their
respective officers, directors, employees, shareholders, insurers, agents, trustees, attorneys,
heirs, administrators, executors, successors and assigns (collectively, “Alma Releasors”),
does hereby, jointly and severally, remise, release and forever discharge Palomar and all Palomar
Affiliates, together with (as applicable) all of their respective officers, directors, employees,
shareholders, insurers, licensees, sublicensees, customers, agents, trustees, attorneys,

2

 

Settlement Agreement

parents,
subsidiaries, successors and assigns (collectively, the “Released Palomar
Entities”), of and from any and all actions, causes of action, claims, counterclaims, damages,
debts, demands, liabilities, costs, expenses, loss, liens and obligations of whatsoever name and
nature, including attorney and professional fees, whether at law or in equity (hereinafter,
“Claims”), in the Professional Field only, which the Alma Releasors now have or ever had
against the Released Palomar Entities, whether or not the facts giving rise to such Claims are now
known or unknown, from the first day of the world to the Effective Date (but not thereafter), which
Claims are asserted or could have been asserted in the Lawsuit, and which further involve and are
limited to the Anderson Patents. It is the intention of the Alma Releasors fully, finally and
forever to release the Released Palomar Entities from Claims released by this Section 4(a)(i). In
furtherance of such intention, this release shall be and remain in effect notwithstanding the
discovery subsequent to the Effective Date of any presently existing fact. Notwithstanding the
foregoing, it is expressly understood that this release does not release the Released Palomar
Entities or any of them from the obligations set forth in this Agreement, the Exhibits hereto and
the other documents delivered at the Closing (including, with respect to Palomar and the Palomar
Affiliates, the Patent License Agreement and TDS Agreement).

               (ii) Of General. Each Alma Releasor does hereby, jointly and severally, remise, release and
forever discharge General, together with (as applicable) all of its officers, directors, employees,
shareholders, insurers, licensees, sublicensees, customers, agents, trustees, attorneys, parents,
subsidiaries, successors and assigns (collectively, the
“Released General Entities”), of
and from any and all Claims, in the Professional Field only, which the Alma Releasors now have or
ever had against the Released General Entities, whether or not the facts giving rise to such Claims
are now known or unknown, from the first day of the world to the Effective Date (but not
thereafter), which Claims are asserted or could have been asserted in the Lawsuit, and which
further involve and are limited to the Anderson Patents. It is the intention of the Alma Releasors
fully, finally and forever to release the Released General Entities from Claims released by this
Section 4(a)(ii). In furtherance of such intention, this release shall be and remain in effect
notwithstanding the discovery subsequent to the Effective Date of any presently existing fact.
Notwithstanding the foregoing, it is expressly understood that this release does not release the
Released General Entities or any of them from the obligations set forth in this Agreement, the
Exhibits hereto and the other documents delivered at the Closing.

          (b) Alma’s Representation, Warranty and Indemnity as to Released Matters.

               (i) To Palomar. Alma represents and warrants to Palomar that it has not heretofore assigned,
transferred or purported to assign or transfer, and that it shall not hereafter assign or transfer
or purport to assign or transfer, to any person or entity any matter it has released in Section
4(a)(i) and it agrees to indemnify and hold harmless the Released Palomar Entities from and against
all Claims based on, resulting from, in connection with, or arising out of, any such assignment or
transfer or purported or claimed assignment or transfer of any such matter that it has released in
Section 4(a)(i), in whole or in part.

               (ii) To General. Alma represents and warrants to General that it has not heretofore assigned,
transferred or purported to assign or transfer, and that it shall not
hereafter assign or transfer or purport to assign or transfer, to any person or entity any
matter it has released in Section 4(a)(ii) and it agrees to indemnify and hold harmless the
Released General

3

 

Settlement Agreement

Entities from and against all Claims based on, resulting from, in connection with, or arising out
of, any such assignment or transfer or purported or claimed assignment or transfer of any such
matter that it has released in Section 4(a)(ii), in whole or in part.

     (c) Release of Alma by Palomar and General.

               (i) By Palomar. Each of Palomar and all Palomar Affiliates, together with (as applicable)
their respective officers, directors, employees, shareholders, insurers, agents, trustees,
attorneys, heirs, administrators, executors, successors and assigns
(collectively, “Palomar
Releasors”), does hereby, jointly and severally, remise, release and forever discharge Alma and
all Alma Affiliates, together with (as applicable) their officers, directors, employees,
shareholders, insurers, licensees, sublicensees, customers, agents, trustees, attorneys, parents,
subsidiaries, successors and assigns (collectively, the “Released Alma Entities”), of and
from any and all Claims, in the Professional Field only, which the Palomar Releasors now have or
ever had against the Released Alma Entities, whether or not the facts giving rise to such Claims
are now known or unknown, from the first day of the world to the Effective Date (but not
thereafter), which Claims are asserted or could have been asserted in the Lawsuit, and which
further involve and are limited to the Anderson Patents. It is the intention of the Palomar
Releasors fully, finally and forever to release the Released Alma Entities from Claims released by
this Section 4(c)(i). In furtherance of such intention, this release shall be and remain in effect
notwithstanding the discovery subsequent to the Effective Date of any presently existing fact.

               (ii) By General. General, together with (as applicable) its respective officers, directors,
employees, shareholders, insurers, agents, trustees, attorneys, heirs, administrators, executors,
successors and assigns (collectively, “General Releasors”), does hereby, jointly and
severally, remise, release and forever discharge the Released Alma Entities, of and from any and
all Claims, in the Professional Field only, which the General Releasors now have or ever had
against the Released Alma Entities, whether or not the facts giving rise to such Claims are now
known or unknown, from the first day of the world to the Effective Date (but not thereafter), which
Claims are asserted or could have been asserted in the Lawsuit, and which further involve and are
limited to the Anderson Patents. It is the intention of the General Releasors fully, finally and
forever to release the Released Alma Entities from Claims released by this Section 4(c)(ii). In
furtherance of such intention, this release shall be and remain in effect notwithstanding the
discovery subsequent to the Effective Date of any presently existing fact.

               (iii) Miscellaneous. Notwithstanding the foregoing in Section 4(c)(i) and 4(c)(ii), it is
expressly understood that the releases by Palomar Releasors and General Releasors contained in this
Agreement do not release the Released Alma Entities or any of them from the obligations set forth
in this Agreement, the Exhibits hereto and the other documents delivered at the Closing (including
the Patent License Agreement and TDS Agreement, or the obligation to pay any amounts under the
terms of Section 3 hereof, Section 4.2 of the Patent License Agreement or Section 4.4 of the Patent
License Agreement (with respect to Sales of Licensed Products by Alma and Alma Affiliates occurring
on or after the Effective Date) each of which may be audited pursuant to those Sections and Section
4.10 of the Patent License Agreement, or Sections 4(a)(i) and 4(b)(i) of the TDS Agreement, which
may be audited pursuant to Sections 4(a)(iii) and 4(b)(iii), respectively, of the TDS Agreement).
For the

4

 

Settlement Agreement

avoidance of doubt, Alma’s obligation to pay to Palomar patent royalties due on Sales of Licensed
Products occurring on or after the Effective Date pursuant to the terms of the Patent License
Agreement shall apply on and after Effective Date, notwithstanding any release contained herein.

          (d) Palomar’s and General’s Representation, Warranty and Indemnity as to Released
Matters. Each of Palomar and General represents and warrants to Alma that it has not heretofore
assigned, transferred or purported to assign or transfer, and shall not hereafter assign or
transfer or purport to assign or transfer, to any person or entity any matter it has released in
Section 4(c) and agrees to indemnify and hold harmless the Released Alma Entities from and against
all Claims based on, resulting from, in connection with, or arising out of, any such assignment or
transfer or purported or claimed assignment or transfer of any such matter that it has released
hereunder, in whole or in part. Nothing in this Section 4(d) shall preclude General from granting
any licenses under the Anderson Patents to another party or parties if the MGH Agreement is
terminated for any reason prior to the expiration of all the Valid Claims of the Anderson Patents.

          (e) Full Settlement. The Parties understand and agree that this Agreement and the
attached Exhibits as executed and delivered at the Closing are intended to settle all disputes (in
existence from the first day of the world to the Effective Date (but not thereafter)) between
Palomar and General on the one hand and Alma on the other hand based on or related in any way to
the Lawsuit and all the other matters released by this Section 4, and which further involve and are
limited to the Anderson Patents, and shall be effective as a full and final accord and satisfaction
and release of all such matters.

     5. Representations and Warranties; Disclaimers. 

          (a) Representations and Warranties by the Parties. Each Party represents and warrants
to the other Parties as of the Effective Date:

               (i) that it is an entity duly organized, validly existing and in good standing under the laws
of the state of its organization, and has full corporate power and authority and the legal right to
own and operate its property and assets and to carry on its business as it is now being conducted
and as it is contemplated to be conducted by this Agreement;

               (ii) that it has the authority to (i) enter into this Agreement, (ii) extend the releases and
rights granted to the other Parties under this Agreement, and (iii) undertake and fully perform its
obligations under this Agreement;

               (iii) that this Agreement has been duly executed and delivered by it and is a binding
obligation of it, enforceable in accordance with its terms, subject, as to enforcement of remedies,
to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting
creditors’ rights generally, and to general equitable principles;

               (iv) its execution, delivery, granting of releases and rights and performance of its
obligations under this Agreement does not and will not, with or without the passage of time or the
giving of notice or both, conflict with or result in any breach of any of the terms, conditions or
provisions of, or constitute a default (or give rise to any right of termination,

5

 

Settlement Agreement

cancellation or acceleration) under any agreement or other document or instrument to which it is a
party; and

               (v) all necessary consents, approvals and authorizations of all regulatory and governmental
authorities and other third parties (including, in the case of Alma, any Alma Affiliates and, in
the case of Palomar, any Palomar Affiliates) required to be obtained by it in connection with the
execution and delivery of this Agreement and the performance of its obligations hereunder have been
obtained.

          (b) Disclaimer. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NONE OF THE PARTIES MAKES ANY
REPRESENTATIONS OR WARRANTIES OF ANY KIND HEREUNDER, WHETHER EXPRESS OR IMPLIED, AND EXPRESSLY
DISCLAIMS ANY AND ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED, INCLUDING ALL WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NONINFRINGEMENT. TO THE EXTENT THIS
PROVISION CONFLICTS IN ANY WAY WITH THE TERMS AND CONDITIONS OF THE MGH AGREEMENT, THE MGH
AGREEMENT SHALL CONTROL.

          (c) No Consequentials. IN NO EVENT SHALL ANY PARTY BE LIABLE TO ANY OTHER HEREUNDER
FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH
OF CONTRACT, TORT (INCLUDING NEGLIGENCE), PRODUCT LIABILITY, OR OTHERWISE, AND WHETHER OR NOT SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. TO THE EXTENT THIS PROVISION CONFLICTS IN
ANY WAY WITH THE TERMS AND CONDITIONS OF THE MGH AGREEMENT, THE MGH AGREEMENT SHALL CONTROL.

     6. Miscellaneous.

          (a) Entire Agreement; Counterparts; Stipulated Dismissal. This Agreement (including
the Exhibits) constitutes the entire agreement between Palomar and MGH on the one hand and Alma on
the other hand relating to the subject matter hereof and supersedes all previous agreements,
practices or courses of dealings between the Parties, whether written or oral, relating to the
subject matter hereof, provided that that certain Rule 408 – Confidentiality Agreement, dated as of
February 14, 2006, between Palomar and Alma shall terminate as of the Effective Date as to any
disclosures occurring after the Effective Date, but shall remain in full force and effect with
respect to all applicable disclosures occurring and rights and obligations accruing prior to the
Effective Date. This Agreement may be executed in counterparts with the same force and effect as if
each of the signatories had executed the same instrument.

          (b) Other Parties. This Agreement shall be binding upon, and inure to the benefit of,
the legal representatives, successors and permitted assigns of the Parties. There shall be no Third
Party beneficiaries, either express or implied, to this Agreement, provided that Section 4 is
intended to benefit, in addition to the Parties, the other Released Palomar Entities, Released
General Entities and Released Alma Entities as if they were Parties hereto.

6

 

Settlement Agreement

          (c) No Agency or Joint Venture Relationship. Nothing contained herein shall be deemed
to create any association, partnership, joint venture or relationship of principal, agent, master
or servant between the Parties hereto or, in the case of Palomar, any Palomar Affiliates, or, in
the case of Alma, any Alma Affiliates, or to provide any
Party with the right, power or authority to incur any obligation or make any representations,
warranties or guarantees on behalf of any other Party.

          (d) Retained Rights. Except as provided in Section 4.7 of the Patent License
Agreement, the Parties retain their rights to petition an appropriate court regarding any breach or
violation of the terms or conditions of this Agreement, a Consent Judgment or the Patent License
Agreement or TDS Agreement.

          (e) Severability. If any term, covenant or condition of this Agreement or the
application thereof to any Party or circumstance shall, to any extent, be held to be invalid or
unenforceable by a court of competent jurisdiction, then (i) the remainder of this Agreement, or
the application of such term, covenant or condition to Parties or circumstances other than those
that were held invalid or unenforceable, shall not be affected thereby and each term, covenant or
condition of this Agreement shall be valid and be enforced to the fullest extent permitted by law;
and (ii) the Parties hereto covenant and agree to renegotiate any such invalid or unenforceable
term, covenant or application thereof in good faith in order to provide a reasonably acceptable
alternative to the term, covenant or condition of this Agreement or the application thereof that is
invalid or unenforceable, it being the intent of the Parties that the basic purposes of this
Agreement are to be effectuated.

          (f) Waivers; Amendments; Supplements. No waiver by any Party of a breach of any
covenant or condition of this Agreement by another Party shall be construed to be a waiver of any
succeeding breach of the same or any other covenant or condition. Except as otherwise expressly
provided herein, this Agreement or any Exhibit hereunder may not be changed or amended except by a
writing expressly referring to this Agreement signed by all the Parties.

          (g) Section 1542 of the California Civil Code. The Parties waive all rights they may
have under Section 1542 of the California Civil Code, and acknowledge that subject to the terms
herein, the releases granted by the Parties extend to all claims
expressly released by Section
4(a)
and 4(c), whether such claims are known or unknown. The Parties are fully informed of the
provisions of Section 1542, which provides that:

“A general release does not extend to claims which the creditor does not know or suspect
to exist in his favor at the time of executing the release, which if known by him must
have materially affected his settlement with the debtor.”

          (h) Publicity and Disclosure of Terms of this Agreement and the Patent License Agreement
and TDS Agreement. The Parties acknowledge that the initial public announcements of the
execution of this Agreement and the Patent License Agreement and TDS Agreement shall be in the
forms of press releases attached hereto as Exhibit E (Palomar’s press release) and
Exhibit F (Alma’s press release). The foregoing does not constitute Palomar’s approval of
Alma’s press release or Alma’s approval of Palomar’s press release. The Parties also agree that
Palomar and Alma will file a copy of this Agreement, the Patent License Agreement, the TDS

7

 

Settlement Agreement

Agreement, the Consent Judgment and the Stipulated Dismissal With Prejudice (in each case without
redaction) with the United States Securities and Exchange Commission and other similar or
comparable governmental bodies, authorities or agencies, if necessary.

          (i) Jurisdiction. Subject to and without limiting Section 4.7 of the Patent License
Agreement, the Parties hereby irrevocably consent to the exclusive jurisdiction and venue of any
state or federal court sitting in the Commonwealth of Massachusetts, over any action or proceeding
arising out of or relating to this Agreement or any agreement or document delivered in connection
herewith or therewith, and agree that all claims in respect of such action or proceeding may be
heard and determined in such state or federal court. Each of the Parties consents to the
jurisdiction of such court or courts for such actions or proceedings and agrees that the service
upon it of a summons and complaint by certified mail return receipt requested shall be sufficient
for such court or courts to exercise personal jurisdiction over the Parties for such actions or
proceedings. The Parties waive any objection to any action or proceeding relating to this Agreement
in any state or federal court sitting in the Commonwealth of Massachusetts, on the basis of forum
non conveniens, lack of personal jurisdiction or otherwise. Notwithstanding the foregoing, if any
action or proceeding may not be brought in any such court because all such courts lack subject
matter jurisdiction, the Parties may bring such action or proceeding in a court of appropriate
jurisdiction.

          (j) Governing Law. This Agreement shall be governed by, and construed and enforced in
accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to its
principles of conflicts of laws; provided that any dispute relating to the scope, validity,
enforceability, infringement or misuse of any Patent shall be governed by, and construed and
enforced in accordance with, the substantive laws of the jurisdiction in which such Patent
originates.

          (k) Further Actions. Each Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

          (l) Parties Advised by Counsel. This Agreement has been negotiated between unrelated
Parties who are sophisticated and knowledgeable in the matters contained in this Agreement and who
have acted in their own self interest. In addition, each Party has been represented by legal
counsel. This Agreement shall not be interpreted or construed against any Party to this Agreement
because that Party or any attorney or representative for that Party drafted or participated in the
drafting of this Agreement.

          (m) Notices. All notices, demands, requests, approvals, consents or other
communications to be given or delivered under this Agreement shall be in writing and shall be
deemed to have been given: (i) when delivered in person or by courier or confirmed facsimile; (ii)
upon confirmation of receipt when sent by certified mail, return receipt requested; or (iii) upon
receipt when sent by reputable private international courier with established tracking capability
(such as DHL, FedEx, or UPS), postage pre-paid, and addressed as set forth as the case may be, to
the noticed Party at the address set forth below, or such other address as a Party may specify by
written notice to the other.

8

 

Settlement Agreement

	 	 	 	 	 	 
	 	Notices shall be sent to Palomar at:
	 	 	 	 
	 	 
	 	 	 	 
	 	Palomar Medical Technologies
	 	 	 	 
	 	82 Cambridge Street
	 	 	 	 
	 	Burlington, MA 01803
	 	 	 	 
	 	Attention: CEO
	 	 	 	 
	 	Facsimile: (781) 993-2377
	 	 	 	 
	 	 
	 	 	 	 
	 	with a required copy to:
	 	 	 	 
	 	 
	 	 	 	 
	 	Palomar Medical Technologies
	 	 	 	 
	 	82 Cambridge Street
	 	 	 	 
	 	Burlington, MA 01803
	 	 	 	 
	 	Attention: General Counsel
	 	 	 	 
	 	Facsimile: (781) 993-2377
	 	 	 	 
	 	 
	 	 	 	 
	 	and a further required copy to:
	 	 	 	 
	 	 
	 	 	 	 
	 	Goodwin Procter llp
	 	 	 	 
	 	Exchange Place
	 	 	 	 
	 	53 State Street
	 	 	 	 
	 	Boston, MA 02109
	 	 	 	 
	 	Attention: Kingsley Taft, Esq.
	 	 	 	 
	 	Facsimile: (617) 523-1231
	 	 	 	 
	 	 
	 	 	 	 
	 	and to General at:
	 	 	 	 
	 	 
	 	 	 	 
	 	Corporate Sponsored Research and Licensing
	 	 	 	 
	 	Massachusetts General Hospital
	 	 	 	 
	 	13th St. BLVD., BLDG. 149 Suite 5036
	 	 	 	 
	 	Charlestown, MA 02129
	 	 	 	 
	 	Attention: Frances Toneguzzo, Ph. D.
	 	 	 	 
	 	Facsimile: (617) 726-8608
	 	 	 	 
	 	 
	 	 	 	 
	 	with a required copy to:
	 	 	 	 
	 	 
	 	 	 	 
	 	Office of the General Counsel
	 	 	 	 
	 	Partners HealthCare System, Inc.
	 	 	 	 
	 	50 Staniford St., Suite 1000
	 	 	 	 
	 	Boston, MA 02114
	 	 	 	 
	 	Attention: Paul G. Cushing, Esq.
	 	 	 	 
	 	Facsimile: (617) 726-1665
	 	 	 	 

9

 

Settlement Agreement

	 	 	 	 	 	 
	 	and to Alma at:
	 	 	 	 
	 	 
	 	 	 	 
	 	Alma Lasers, Inc.
	 	 	 	 
	 	485 Half Day Road #100
	 	 	 	 
	 	Buffalo Grove, IL 60089
	 	 	 	 
	 	Attention: Howard Kelly
	 	 	 	 
	 	Facsimile: 224-377-2050
	 	 	 	 

          (n) Captions, Section Headings. As used in this Agreement, “including” means
“including but not limited to”, and “herein”, “hereof”, and “hereunder” refer to this Agreement as
a whole. The Section headings used herein are for reference and convenience only, and shall not
enter into the interpretation of this Agreement. Unless otherwise expressly provided herein, any
reference to a number of “days” hereunder shall refer to calendar days. References to Sections
include subsections, which are part of the related Section (e.g., a section numbered “Section 4(a)”
would be part of “Section 4”, and
references to “Section 5(a)” would also refer to material contained in the subsection
described as “Section 5(a)(ii)”).

          (o) Capitalized Terms. Capitalized terms used but not defined herein shall have the
meaning ascribed to them in the Patent License Agreement.

          (p) Mistakes of Fact or Law. Mistakes of fact or law shall not constitute grounds for
modification, avoidance or rescission of the terms of this Agreement.

[remainder of this page intentionally left blank]

10

 

Settlement Agreement

     IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have each caused
its duly authorized representative to execute and deliver this Agreement under seal as of the
Effective Date.

	 	 	 	 	 
	Palomar
Medical Technologies Inc.
	 
	 	 	 	 
	By:

	 	/s/ Joseph P. Caruso	 	 
	 

	 	 

Name: Joseph P. Caruso
	 	 
	 

	 	Title: CEO	 	 
	 

	 	Date: 3/29/07	 	 
	 
	 	 	 	 
	The General Hospital Corporation
	 
	 	 	 	 
	By:
	 	/s/ Frances Toneguzzo	 	 
	 

	 	 

Name: Frances Toneguzzo, Ph. D.
	 	 
	 

	 	Title: Director, Corporate Sponsored Research & Licensing	 	 
	 

	 	Date: 3/29/07	 	 
	 
	 	 	 	 
	Alma Lasers, Inc.
	 
	 	 	 	 
	By:
	 	/s/ Howard Kelly	 	 
	 

	 	 

Name: Howard Kelly
	 	 
	 

	 	Title: CEO	 	 
	 
	 	Date: 	 	 

 

 

Exhibit A

Patent License Agreement

 

 

Exhibit B

TDS Agreement

 

 

Exhibit C

Consent Judgment

 

 

Exhibit D

Stipulated Dismissal With Prejudice

 

 

Settlement Agreement

Exhibit E

Palomar Press Release

     NEWS RELEASE for April 2, 2007 at 8:30 AM EST 

	 	 	 
	Contacts:

	 	Investor Relations
	 

	 	Kayla Castle
	 

	 	Investor Relations Manager
	 

	 	Palomar Medical Technologies Inc
	 

	 	781-993-2411
	 

	 	ir@palomarmedical.com

ALMA ADMITS INFRINGEMENT AND VALIDITY OF PALOMAR PATENTS

AND AGREES TO CHANGE TRADE DRESS

Alma to pay 11.0% for past patent and trade dress infringement

     BURLINGTON, MA (April 2, 2007) ... Palomar Medical Technologies Inc
(Nasdaq:PMTI) announced today the resolution of its on-going patent infringement and trade dress
infringement lawsuit against Alma Lasers, Inc. Palomar accused Alma’s Harmony, Soprano, Soprano XL
and Sonata Systems of infringing U.S. Patent Nos. 5,735,844 and 5,595,568 (the “Patents”). Palomar
has an exclusive license to these patents from the General Hospital Corporation in Boston,
Massachusetts. Palomar also accused Alma’s Harmony System of infringing the distinctive trade dress
of Palomar’s StarLux System.

     Alma has admitted to the infringement, validity and enforceability of the Patents and has
agreed not to challenge them in the future. Alma has also agreed to change the trade dress of the
Harmony and Aria Systems within the next six to nine months.

     Alma will pay Palomar a 9.5% patent royalty plus interest on prior sales of their laser and
lamp based hair removal systems beginning with their initial sales in 2003 and a 1.5% trade dress
fee plus interest on prior sales of their Harmony and Aria systems. Those amounts will be
determined based on an audit by an independent auditor that will be conducted over the next few
months, and Palomar will recognize those amounts only after they are determined as part of that
audit. In addition, Alma will pay Palomar for its legal costs incurred during the lawsuit. From
March 28, 2007 through December 31, 2007, Alma will pay Palomar an 8.5% patent royalty and,
beginning on January 1, 2008, Alma will pay Palomar a 7.5% patent royalty on future sales of
current and any new light-based hair removal systems. The terms are in accordance with Palomar’s
standard license terms including combination systems that include multiple light sources for hair
removal and other applications.

     Patricia Davis, Senior Vice President and General Counsel of Palomar, commented “The
resolution of this lawsuit against Alma as well as the resolution last spring of the lawsuits
against Cutera demonstrate the strength of Palomar’s patent portfolio. As in the past, when forced
to

i

 

Settlement Agreement

litigate, we will seek higher royalties than when competitors take a license on a voluntary basis.
As we announced on November 7, 2006, our license agreement with Cynosure was on more favorable
terms simply because we were not forced to sue Cynosure prior to executing the license. We have
notified our unlicensed competitors that for now Palomar remains willing to offer licenses. Our
willingness and the rates of such licenses, however, may change as competitors continue to wait for
us to sue them for patent infringement.”

     Joseph P. Caruso, President and Chief Executive Officer of Palomar, commented, “This favorable
resolution with Alma so early in this litigation further substantiates the strength of these
patents. Palomar pioneered the cosmetic light based industry with the first high powered light
based hair removal system in 1997. Since then, this industry has become one of the fastest growing
segments in the medical industry with hair removal procedures being the most popular cosmetic light
based procedure performed today. Many companies have taken advantage of this high growth by
offering products covered by patents controlled by Palomar, and we intend to continue to enforce
our intellectual property. This strategy provides significant financial benefit to Palomar and its
shareholders.”

     Mr. Caruso continued, “We were also able to force Alma to change the look of their products on
a worldwide basis. Over the past few years the market has confused their products with ours and
Alma has been able to sell their product based on the reputation of Palomar. Our sales and
marketing group will now be free to address the growing market for light-based aesthetic products
without this confusion.”

     Under Palomar’s license agreement with the General Hospital Corporation, Palomar will pay to
the General Hospital Corporation 40% of all payments from Alma excluding Palomar’s legal costs and
the trade dress fees.

     For more information, please see the Settlement Agreement, the Non-Excluive Patent License
Agreement, the Trade Dress Settlement Agreement, the Consent Judgments and Stipulations of
Dismissal filed as Exhibits 10.1, 10.2, 10.3, 10.4 and 10.5 to a Current Report on Form 8-K filed
today.

About Palomar Medical Technologies, Inc: Palomar is a leading researcher and developer of
light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field,
when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of
the major advances in light-based hair removal have been based on Palomar technology. On December
8, 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from
the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based
hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers
without a prescription. There are now millions of light-based cosmetic procedures performed around
the world every year in physician offices, clinics, spas and salons. Palomar is testing many new
and exciting applications to further advance the hair removal market and other cosmetic
applications. Palomar is focused on developing proprietary light-based technology for introduction
to the mass markets. Palomar has an agreement with The Gillette Company to develop and potentially
commercialize a patented home-use, light-based hair removal device for women. Palomar also has an
agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize
home-use,

ii

 

Settlement Agreement

light-based devices for reducing or reshaping body fat including cellulite, reducing the
appearance of skin aging, and reducing or preventing acne.

For more information on Palomar and its products, visit Palomar’s website at
www.palomarmedical.com. To continue receiving the most up-to-date information and
latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the
Investor Relations’ section of the website.

With the exception of the historical information contained in this release, the matters described
herein contain forward-looking statements, including but not limited to statements relating to new
markets, future royalty amounts due from third parties, development and introduction of new
products, and financial and operating projections. These forward-looking statements are neither
promises nor guarantees, but involve risk and uncertainties that may individually or mutually
impact the matters herein, and cause actual results, events and performance to differ materially
from such forward-looking statements. These risk factors include, but are not limited to, results
of future operations, technological difficulties in developing or introducing new products, the
results of future research, lack of product demand and market acceptance for current and future
products, the effect of economic conditions, challenges in managing joint ventures and research
with third parties and government contracts, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether FDA clearance will be
obtained for future products and additional applications, the results of litigation, difficulties
in collecting royalties, potential infringement of third-party intellectual property rights,
factors affecting the Company’s future income and resulting ability to utilize its NOLs, and/or
other factors, which are detailed from time to time in the Company’s SEC reports, including the
report on Form 10-K for the year ended December 31, 2006 and the Company’s quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. The Company undertakes no obligation to release publicly
the result of any revisions to these forward-looking statements that may be made to reflect events
or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

	 	 	 
	Contact: Kayla Castle

	 

	 	Investor Relations Manager Palomar
	 

	 	Medical Technologies, Inc.

 781-993-2411
	 

	 	ir@palomarmedical.com

iii

 

Settlement Agreement

Exhibit F

Alma Press Release

Alma Lasers and Palomar Medical Technologies settle Infringement Lawsuit

Buffalo Grove, Illinois, April 2, 2007—Howard Kelly, Chief Executive Officer of Alma Lasers,
announced today that Alma Lasers, Ltd. and Palomar Medical Technologies, Inc. have settled their
civil action filed in the United States District Court for the District of Massachusetts. The suit
involves certain US hair removal patents owned by
Massachusetts General Hospital and licensed exclusively to Palomar.

Under the SETTLEMENT AGREEMENT, Alma Lasers obtains a non-exclusive license to utilize the patented
technology in its product line. “With the best interests of Alma Lasers’ customers in mind, we
decided to enter into a licensing agreement with
Palomar.” explained Mr. Kelly. Through the settlement, Alma Lasers has avoided a
potentially long and expensive legal battle.

In practical terms, the settlement means Alma Lasers can continue its strategy of innovation
through technology without interruption. “Because we’ve removed these patent issues with Palomar,”
said Mr. Kelly, “the leadership and product development teams at Alma Lasers will be able to focus
solely on achieving our core vision—to be a global leader in providing technology-based solutions
to the aesthetic marketplace.”

About Alma Lasers, Ltd.

Alma Lasers, Ltd. is a global developer, manufacturer and seller of laser, light-based and
radiofrequency devices for aesthetic and medical applications. Since 1980, the founders of Alma
Lasers have been at the forefront of innovative laser, light-based and RF medical technology. Their
technical expertise and in-depth understanding of practitioners’ needs led to the development of
Alma Lasers’ multi-technology/multi-application systems. Alma Lasers’ mission is to provide
modular, cost-effective and high performance designs that enable medical practitioners to
confidently offer safe, effective and profitable aesthetic treatments to their patients. More
information about Alma Lasers can be found at
www.almalasers.com.

Contact:

Yariv Matzliach, Executive Vice President, Global Marketing

Tel: 1-866-414-2562

Yarivm@almalasers.comexv10w23

 

EXHIBIT 10.23

TRADE DRESS SETTLEMENT AGREEMENT

     THIS TRADE DRESS SETTLEMENT AGREEMENT (this “TDS Agreement”) is made and entered into
as of the 29th day of March, 2007 (the “Effective Date”) by and among Palomar Medical
Technologies, Inc., a Delaware corporation, with offices at 82 Cambridge Street, Burlington, MA
01803 (“Palomar”), Alma Lasers, Inc., a Delaware corporation with offices at 485 Half Day
Road #100, Buffalo Grove, IL 60089 (“Alma USA”), and Alma Lasers, Ltd., an Israeli company with
offices at 7 Halamish Street, Caesarea Industrial Park, Caesarea, Israel 38900 (Alma USA and Alma
Lasers, Ltd., collectively, “Alma”) (Palomar, on the one hand, and Alma together with all
Alma Affiliates, on the other hand, each a “Party”, and together, the “Parties”) .

     WHEREAS, Palomar and Alma USA are parties to a lawsuit captioned: “Palomar Medical
Technologies, Inc. v. Alma Lasers, Inc.” Case No. 1:06-CV-11171, which is currently pending in the
United States District Court for the District of Massachusetts (the “Lawsuit”), which
lawsuit shall be settled and compromised in accordance with this TDS Agreement and that certain
Settlement Agreement, to be executed contemporaneously with this Agreement, by and among Palomar,
The General Hospital Corporation and Alma USA (the “Settlement Agreement”), and that
certain Patent License Agreement, to be executed contemporaneously with this Agreement, by and
between Palomar and Alma (the “Patent License Agreement”);

     WHEREAS, the Lawsuit generally concerns, among other things, allegations of infringement of
the trade dress of Palomar’s products by certain of Alma’s products, and any defenses or
counterclaims relating thereto (collectively, the “Trade Dress Claims”); and

     WHEREAS, Palomar and Alma wish to settle and compromise the Trade Dress Claims in the Lawsuit
and agree to other terms governing the Sale, marketing and promotion of Alma Products after the
Effective Date on the terms and conditions set forth below.

     NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the
Parties covenant and agree as follows:

     1. Capitalized Terms. Capitalized terms used but not defined herein or indicated to be
defined in the Settlement Agreement shall have the meaning ascribed to them in the Patent License
Agreement.

     2. Definitions. The following terms (and their correlatives), in addition to terms
defined on first use herein, shall have the meanings set forth below:

          (i) “3-Month Period” shall mean that period of time commencing six (6) months
after the Effective Date and ending on the Cutoff Date.

          (ii) “6-Month Period” shall mean that period of time commencing on the
Effective Date and ending six (6) months after the Effective Date.

          (iii) “9-Month Period” shall mean that period of time commencing on the
Effective Date and ending on the Cutoff Date.

 

 

Trade Dress Settlement Agreement

          (iv) “Approved Trade Dress” shall mean the trade dress set forth
in Exhibit A.

          (v) “Cutoff Date” shall mean the date that is nine (9) months after the
Effective Date.

          (vi) “Existing Trade Dress” shall mean the trade dress of the Harmony System
and/or Aria System used as of the Effective Date, which the Parties acknowledge is set
forth in Exhibit B, or any trade dress substantially similar to such trade dress of
the Harmony System or Aria System used as of the Effective Date.

          (vii) “Fee-Bearing Net Sales” shall mean the Net Sales attributable to all the
components (i.e., the base unit/console and all Alma Modules sold for use with such base
unit/console) of an Alma Product (including the Harmony System and Aria System), whether
one or more Sales were involved.

          (viii) “Permitted Alma Modules” shall mean any Alma Modules that Alma or any
Alma Affiliate Sells with the Existing Trade Dress after the end of the 6-Month Period (the
date of such Sale to be based on the application of U.S. generally accepted accounting
principles, consistently applied) for use with a base unit/console of a Harmony System or
an Aria System, which base unit/console of a Harmony System or Aria System is Sold prior to
the Cutoff Date.

     3. The Closing. Each Party shall execute and deliver this TDS Agreement in connection
with the Closing (as defined in the Settlement Agreement).

     4. Fees for Trade Dress Infringement.

          (a) Pre-Effective Date Infringement.

          (i) Fee. As partial consideration hereunder, Alma shall pay to Palomar, within seven
(7) days of the Effective Date, a trade dress infringement fee equal to one and one-half
percent (1.5%) of the worldwide, Fee-Bearing Net Sales of the Harmony System and Aria
System accruing prior to the Effective Date. Alma represents and warrants that such
aggregate amount is Alma’s good faith estimate of the aggregate trade dress infringement
fee due Palomar for Sales of the Harmony System and Aria System occurring prior to the
Effective Date. For clarity, (i) such Sales shall include Sales of the Harmony System and
Aria System by predecessors in interest to Alma, including MSQ, Ltd. and Orion Lasers, Inc.
and (ii) with respect to Sales of the Harmony System and Aria System by Alma or Alma
Affiliates to Third Party distributors outside the United States for re-Sale outside the
United States, the Fee-Bearing Net Sales for purposes of the foregoing trade dress
infringement fee shall be based on the Sale of such
Harmony System or Aria System by Alma or Alma Affiliates to such Third Party
distributor outside the United States and not the re-Sale of such Harmony System or Aria
System by such Third Party Distributor.

          (ii) Interest. The infringement fee payment set forth in Section 4(a)(i) will include
interest at the Applicable Rate calculated on a compound basis with a calendar

2

 

 Trade Dress Settlement Agreement

quarterly compounding period from the date in the middle of the calendar quarter in which
the applicable Sale was made until the Effective Date.

          (iii) Initial Audit. Beginning within sixty (60) days after the Effective Date, Alma and Alma
Affiliates shall permit the Independent Accountant, which as of the Effective Date is
PriceWaterhouse Coopers LLP, to have access during normal business hours, at Alma and any Alma
Affiliate’s premises, to such of the records of Alma and Alma Affiliates as may be reasonably
necessary to verify the accuracy of the infringement fee payment set forth in Section 4(a)(i) and
applicable interest in Section 4(a)(ii) (the “Initial Audit”), and Alma shall be
responsible for any under-payment of the amount owed Palomar under this Section 4(a)
notwithstanding the terms of this TDS Agreement or the Settlement Agreement (including any release
thereunder). The Parties acknowledge and agree that Alma shall be required to pay any initial
under-payment under this Section 4(a) (the “Past Infringement Under-Payment”) in full, plus
interest at a rate equal to the lesser of one and one-half percent (1.5%) per month or the highest
rate permitted by applicable law (calculated on a compound basis with a monthly compounding period
from the date in the middle of the month in which the Sale was made until the date payment is made,
or if any portion of the Past Infringement Under-Payment cannot reasonably be related to any such
Sale so as to determine the start date for such interest calculation, then from January 1, 2006 for
such portion) (the “Higher Rate”), and not the Applicable Rate, and failure by Alma to pay
the Past Infringement Under-Payment, plus such interest at the Higher Rate, in full within
forty-five (45) days following notice thereof shall constitute a material breach of this TDS
Agreement by Alma. For clarity, only one rate of interest shall apply to any Sale of the Harmony
System or Aria System, or any portion of Fee-Bearing Net Sales, not initially reported by Alma that
gives rise to or results in the Past Infringement Under-Payment, which rate of interest shall be
equal to the Higher Rate as determined above and not the Applicable Rate. The fees and expenses
charged by such Independent Accountant for the Initial Audit shall be paid by Alma.

          (b) Post-Effective Date Infringement.

          (i) Contingent Fee. If Alma or any Alma Affiliate Sells any unit of the Harmony System, Aria
System or any other Alma Products with the Existing Trade Dress during the 3-Month Period (the date
of such Sale to be based on the application of U.S. generally accepted accounting principles,
consistently applied), Alma shall pay to Palomar, within forty-five (45) days of the Cutoff Date, a
trade dress infringement fee
equal to one and one-half percent (1.5%) of the Fee-Bearing Net Sales of all units of (i) the
Harmony System and Aria System accruing during the 9-Month Period, including Alma Modules sold
during such 9-Month Period for use with Harmony System and/or Aria System base units that were Sold
at any time prior to the Cutoff Date, and (ii) if applicable, such other Alma Product Sold with the
Existing Trade Dress accruing prior to the Cutoff Date, in each case of clause (i) and (ii),
regardless of whether some of such units were Sold without the Existing Trade Dress and without
limiting Alma’s and Alma Affiliates’ covenant not to Sell, market or promote the Harmony System,
Aria System or any other Alma Product with the Existing Trade Dress commencing on the Cutoff Date
in accordance with Section 5. For clarity and without limiting the generality of the

3

 

 Trade Dress Settlement Agreement

foregoing, the re-Sale of the Harmony System or Aria System with the Existing Trade Dress by a
Third Party distributor during or after the 3-Month Period, solely in the case in which the
underlying Sale of such Harmony System or Aria System by Alma or any Alma Affiliate to such Third
Party distributor occurred before or during the 6-Month Period, shall not obligate Alma to pay the
foregoing one and one-half percent (1.5%) trade dress infringement fee, provided that the volume of
Sales of the Harmony System and Aria System with the Existing Trade Dress by Alma or any Alma
Affiliate to Third Party distributors during the 6-Month Period does not exceed the volume of such
Sales during the six (6) month period immediately preceding the Effective Date.

          (ii) Interest. The infringement fee payment set forth in Section 4(b) will include interest
at the Higher Rate calculated on a compound basis with a monthly compounding period from the
date in the middle of the month in which the applicable Sale was made until the date payment is
made.

          (iii) Second Audit. Beginning within sixty (60) days after the Cutoff Date, Alma and Alma
Affiliates shall permit an Independent Accountant to have access during normal business hours, at
Alma and any Alma Affiliate’s premises, to such of the records of Alma and Alma Affiliates as may
be reasonably necessary to verify the accuracy of the infringement fee payment set forth in Section
4(b)(i) and applicable interest in Section 4(b)(ii) (the “Second Audit”), and Alma shall be
required to pay any under-payment under this Section 4(a)(iii) notwithstanding the terms of this
TDS Agreement or the Settlement Agreement (including any release thereunder). The Parties
acknowledge and agree that Alma shall be required to pay any initial under-payment under this
Section 4(a)(iii) (the “Future Infringement Under-Payment”) in full, plus interest at the
Higher Rate (calculated on a compound basis with a monthly compounding period from the date in the
middle of the month in which the Sale was made until the date payment is made), and not the
Applicable Rate, and failure by Alma to pay the Future Infringement Under-Payment, plus such
interest at the Higher Rate, in full within forty-five (45) days following notice thereof shall
constitute a material breach of this TDS Agreement by Alma. For clarity, only one rate of interest
shall apply to any Sale of the Harmony System or Aria System, or any portion of Fee-Bearing Net
Sales, not initially reported by Alma that gives rise to or results in the Past Infringement
Under-Payment, which rate of interest shall be equal to the Higher Rate as determined above and not
the Applicable Rate. The
fees and expenses charged by such Independent Accountant for the Second Audit shall be paid by
Alma.

          (c) Permitted Alma Module Infringement.

          (i) Fee. If Alma or any Alma Affiliate Sells any Permitted Alma Modules, Alma shall pay to
Palomar, within forty-five (45) days of the end of each calendar quarter, a trade dress
infringement fee equal to one and one-half percent (1.5%) of the Fee-Bearing Net Sales of all
Permitted Alma Modules accruing during such calendar quarter, without limiting Alma’s and Alma
Affiliates’ covenant not to Sell, market or promote the Harmony System, Aria System or any other
Alma Product with the Existing Trade Dress commencing on the Cutoff Date in accordance with Section
5.

4

 

Trade Dress Settlement Agreement

          (ii) Audit. Such Sales of Permitted Alma Modules that give rise to the infringement
fee payment set forth in Section 4(c)(i) shall be auditable for a period of seven (7) years
from the date of each such Sale. The Parties acknowledge and agree that Alma shall be
required to pay any under-payment under this Section 4(c) (the “Future Permitted Alma
Module Infringement Under-Payment”) in full, plus interest at the Higher Rate
(calculated on a compound basis with a monthly compounding period from the date in the
middle of the month in which the Sale was made until the date payment is made), and failure
by Alma to pay the Future Permitted Alma Module Infringement Under-Payment, plus
such interest at the Higher Rate, in full within forty-five (45) days following notice
thereof shall constitute a material breach of this TDS Agreement by Alma.

          (d) Manner of Payment. The payments contemplated by this Section 4(a) shall be made by
wire transfer, without deduction for any taxes or other charges, in U.S. dollars to the credit of:

          Palomar’s account:

Bank Name: Banknorth 
Bank Address: 370 Main Street
                     Worcester,
MA 01608 
Palomar Medical Technologies, Inc.
 Account No. 8241022982

ABA No. 211370545

          (e) Exclusivity of Trade Dress Infringement Fees. The payments required by this
Section 4(a) are exclusive of any amounts payable by Alma to Palomar pursuant to the Settlement
Agreement, the Patent License Agreement or any other agreement to which Palomar and Alma are
parties.

     5.  Covenants by Alma Regarding Harmony System and Aria System Trade Dress.

          (a) Harmony System and Aria System. Commencing on or before the Cutoff Date and
thereafter, Alma and Alma Affiliates shall not Sell, market or promote the Harmony System and Aria
System (including the base unit and handpieces, but excluding Permitted Alma Modules) with the
Existing Trade Dress, and the sublicense granted in Section 2.1 of the Patent License Agreement to
Alma and Alma Affiliates shall not apply to any Harmony System or Aria System (including the base
unit and handpieces, but excluding Permitted Alma Modules) Sold, marketed or promoted by Alma or
any Alma Affiliates or Alma Sublicensees with the Existing Trade Dress after the Cutoff Date. For
clarity and without limiting the generality of the foregoing, (i) the Sale, marketing or promotion
of the Harmony System and Aria System with the Approved Trade Dress shall not constitute a breach
of the immediately preceding sentence and (ii) the re-Sale of the Harmony System or Aria System
with the Existing Trade Dress by a Third Party distributor on or after the Cutoff Date, solely in
the case in which the underlying Sale of such Harmony System or Aria System by Alma or any Alma
Affiliate to such Third Party distributor occurred before the Cutoff Date, shall not constitute a
breach of the immediately preceding sentence, provided that the volume of underlying Sales of the
Harmony System and

5

 

 Trade Dress Settlement Agreement

Aria System with the Existing Trade Dress by Alma or any Alma Affiliate to Third Party distributors
during the 9-Month Period does not exceed the volume of such Sales during the nine (9) month period
immediately preceding the Effective Date.

          (b) Alma Products. Except as not prohibited with respect to the Harmony System and
Aria System during the 9-Month Period and Permitted Alma Modules, in each case as set forth in
Section 5(a), Alma and Alma Affiliates shall not Sell, market or promote any Alma Products with any
trade dress that is confusingly similar to the trade dress of any products Sold, marketed or
promoted by Palomar or Palomar Affiliates (including without limitation the Existing Trade Dress)
at any time, and the sublicense granted in Section 2.1 of the Patent License Agreement to Alma and
Alma Affiliates shall not apply to any such Alma Products.

          (c) Breach. Without limitation, any breach of this Section 5 shall constitute a
material breach of this TDS Agreement by Alma.

     6. Releases and Indemnities.

          (a) By Palomar.

          (i) Each Palomar Releasor (as defined in the Settlement Agreement) does hereby,
jointly and severally, remise, release and forever discharge the Released Alma Entities (as
defined in the Settlement Agreement) of and from any and all Trade Dress Claims which the
Palomar Releasors now have or ever had against the Released Alma Entities, whether or not
the facts giving rise to such Trade Dress Claims are now known or unknown, from the first
day of
the world to the Effective Date (but not thereafter). It is the intention of the
Palomar Releasors fully, finally and forever to release the Released Alma Entities from
Trade Dress Claims released by this Section 6(a). In furtherance of such intention, this
release shall be and remain in effect notwithstanding the discovery subsequent to the
Effective Date of any presently existing fact.

          (ii) Palomar hereby represents and warrants to Alma that it has not heretofore
assigned, transferred or purported to assign or transfer, and shall not hereafter assign or
transfer or purport to assign or transfer, to any person or entity any matter it has
released in Section 6(a) and agrees to indemnify and hold harmless the Released Alma
Entities from and against all Claims (as defined in the Settlement Agreement) based on,
resulting from, in connection with, or arising out of, any such assignment or transfer or
purported or claimed assignment or transfer of any such matter that it has released
hereunder, in whole or in part.

          (iii) Notwithstanding the foregoing in Section 6(a), it is expressly understood that
the release by Palomar Releasors contained in this TDS Agreement does not release the
Released Alma Entities or any of them from the obligations set forth in this TDS Agreement
and the other documents delivered at the Closing (including the Patent License Agreement
and Settlement Agreement), or the obligation to pay any amounts under the terms of, without
limitation, Section 4 hereof, Section 3 of the Settlement Agreement, Section 4.2 of the
Patent License Agreement or Section 4.4 of the

6

 

 Trade Dress Settlement Agreement

Patent License Agreement, each of which may be audited pursuant to those Sections and
Section 4.10 of the Patent License Agreement, as applicable.

          (b) By Alma.

          (i) Each Alma Releasor (as defined in the Settlement Agreement) does hereby, jointly
and severally, remise, release and forever discharge the Released Palomar Entities (as
defined in the Settlement Agreement) of and from any and all Trade Dress Claims which the
Alma Releasors now have or ever had against the Released Palomar Entities, whether or not
the facts giving rise to such Trade Dress Claims are now known or unknown, from the first
day of the world to the Effective Date (but not thereafter). It is the intention of the
Alma Releasors fully, finally and forever to release the Released Palomar Entities from
Trade Dress Claims released by this Section 6(b). In furtherance of such intention, this
release shall be and remain in effect notwithstanding the discovery subsequent to the
Effective Date of any presently existing fact.

          (ii) Alma hereby represents and warrants to Palomar that it has not heretofore
assigned, transferred or purported to assign or transfer, and shall not hereafter assign or
transfer or purport to assign or transfer, to any person or entity any matter it has
released in Section 6(b) and agrees to indemnify and hold
harmless the Released Palomar Entities from and against all Claims based on, resulting
from, in connection with, or arising out of, any such assignment or transfer or purported
or claimed assignment or transfer of any such matter that it has released hereunder, in
whole or in part.

          (c) Full Settlement. The Parties understand and agree that this TDS Agreement is
intended to settle all disputes (in existence from the first day of the world to the Effective Date
(but not thereafter)) between Palomar and Alma based on or related in any way to the Trade Dress
Claims, and shall be effective as a full and final accord and satisfaction and release of all such
matters.

     7. Representations and Warranties; Disclaimers.

          (a) Representations and Warranties by the Parties. Each Party represents and warrants
to the other Party as of the Effective Date:

          (i) that it is an entity duly organized, validly existing and in good standing under
the laws of the state or other jurisdiction of its organization, and has full corporate
power and authority and the legal right to own and operate its property and assets and to
carry on its business as it is now being conducted and as it is contemplated to be
conducted by this TDS Agreement;

          (ii) that it has the authority to (i) enter into this TDS Agreement, (ii) extend the
releases granted to the other Party under this TDS Agreement, and (iii) undertake and
fully perform its obligations and covenants under this TDS Agreement;

          (iii) that this TDS Agreement has been duly executed and delivered by it and is a
binding obligation of it, enforceable in accordance with its terms, subject, as to

7

 

 Trade Dress Settlement Agreement

enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization
and similar laws affecting creditors’ rights generally, and to general equitable
principles;

          (iv) its execution, delivery, granting of releases and rights and performance of its
obligations under this TDS Agreement does not and will not, with or without the passage of
time or the giving of notice or both, conflict with or result in any breach of any of the
terms, conditions or provisions of, or constitute a default (or give rise to any right of
termination, cancellation or acceleration) under any agreement or other document or
instrument to which it is a party; and

          (v) all necessary consents, approvals and authorizations of all regulatory and
governmental authorities and other third parties (including, in the
case of Alma, any Alma Affiliates and, in the case of Palomar, any Palomar Affiliates)
required to be obtained by it in connection with the execution and delivery of this TDS
Agreement and the performance of its obligations hereunder have been obtained.

          (b) Disclaimer. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR WARRANTIES OF ANY KIND
HEREUNDER, WHETHER EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, WHETHER
EXPRESS OR IMPLIED, INCLUDING ALL WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
TITLE AND NONINFRINGEMENT.

          (c) No Consequentials. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO ANY OTHER HEREUNDER
FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH
OF CONTRACT, TORT (INCLUDING NEGLIGENCE), PRODUCT LIABILITY, OR
OTHERWISE, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

     8. Disputes.

          (a) Disputes. The Parties recognize that disputes as to certain matters may from time
to time arise that relate to any Party’s rights or obligations hereunder. It is the objective of
the Parties to establish procedures to facilitate the resolution of disputes arising under this
Agreement in an expedited manner by mutual cooperation. To accomplish this objective, the Parties
agree to adhere to the procedures set forth in Section 6.1 of the Patent License Agreement if and
when a dispute arises under this Agreement.

          (b) Equitable Relief. Notwithstanding the foregoing dispute resolution procedure, in
the event of an actual or threatened breach hereunder by Alma, Palomar may seek equitable relief
(including restraining orders, specific performance or other injunctive relief) without submitting
to such dispute resolution procedure if there is a reasonable likelihood of the occurrence of
irreparable harm during the period of the dispute resolution procedure.

          (c) Tolling. The Parties agree that all applicable statutes of limitation and
time-based defenses (such as estoppel and laches) shall be tolled while the dispute resolution

8

 

Trade Dress Settlement Agreement

procedure set forth in Section 6.1 of the Patent License Agreement is pending, and the
Parties shall cooperate in taking any and all actions necessary to achieve such a result.

     9. Miscellaneous.

          (a) Entire Agreement; Counterparts. This TDS Agreement (including the Exhibits)
constitutes the entire agreement between Palomar and Alma relating to the subject matter hereof and
supersedes all previous agreements, practices or courses of dealings between the Parties, whether
written or oral, relating to the subject matter hereof, provided that that certain Rule 408 –
Confidentiality Agreement, dated as of February 14, 2006, between Palomar and Alma shall terminate
as of the Effective Date as to any disclosures occurring after the Effective Date, but shall remain
in full force and effect with respect to all applicable disclosures occurring and rights and
obligations accruing prior to the Effective Date. This TDS Agreement may be executed in
counterparts with the same force and effect as if each of the signatories had executed the same
instrument.

          (b) Other Parties. This TDS Agreement shall be binding upon, and inure to the benefit
of, the legal representatives, successors and permitted assigns of the Parties. There shall be no
Third Party beneficiaries, either express or implied, to this TDS Agreement, provided that Section
6 is intended to benefit, in addition to the Parties, the other Released Palomar Entities and
Released Alma Entities as if they were Parties hereto.

          (c) No Agency or Joint Venture Relationship. Nothing contained herein shall be deemed
to create any association, partnership, joint venture or relationship of principal, agent, master
or servant between the Parties hereto or, in the case of Palomar, any Palomar Affiliates, or, in
the case of Alma, any Alma Affiliates, or to provide any Party with the right, power or authority
to incur any obligation or make any representations, warranties or guarantees on behalf of the
other Party.

          (d) Retained Rights. Except as provided in Section 4.7 of the Patent License
Agreement, the Parties retain their rights to petition an appropriate court regarding any breach or
violation of the terms or conditions of this TDS Agreement, a Consent Judgment or the Patent
License Agreement or Settlement Agreement.

          (e) Severability. If any term, covenant or condition of this TDS Agreement or the
application thereof to any Party or circumstance shall, to any extent, be held to be invalid or
unenforceable by a court of competent jurisdiction, then (i) the remainder of this TDS
Agreement, or the application of such term, covenant or condition to Parties or circumstances other
than those that were held invalid or unenforceable, shall not be affected thereby and each term,
covenant or condition of this TDS Agreement shall be valid and be enforced to the fullest extent
permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate any such invalid or
unenforceable term, covenant or application thereof in good faith in order to provide a reasonably
acceptable alternative to
the term, covenant or condition of this TDS Agreement or the application thereof that is invalid or
unenforceable, it being the intent of the Parties that the basic purposes of this TDS Agreement are
to be effectuated.

9

 

 Trade Dress Settlement Agreement

          (f) Waivers; Amendments; Supplements. No waiver by any Party of a breach of any
covenant or condition of this TDS Agreement by the Party shall be construed to be a waiver of any
succeeding breach of the same or any other covenant or condition. Except as otherwise expressly
provided herein, this TDS Agreement or any Exhibit hereunder may not be changed or amended except
by a writing expressly referring to this TDS Agreement signed by all the Parties.

          (g) Section 1542 of the California Civil Code. The Parties waive all rights they may
have under Section 1542 of the California Civil Code, and acknowledge that subject to the terms
herein, the releases granted by the Parties extend to all claims expressly released by Section 6,
whether such claims are known or unknown. The Parties are fully informed of the provisions of
Section 1542, which provides that:

“A general release does not extend to claims which the creditor does not know or suspect
to exist in his favor at the time of executing the release, which if known by him must
have materially affected his settlement with the debtor.”

          (h) Publicity and Disclosure of Terms of
this TDS Agreement and the Patent License Agreement and TDS Agreement.
The Parties agree that the initial public
announcements of the execution of this TDS Agreement shall be as set forth in
Section 6(h) of the Settlement Agreement. Alma also agrees that Palomar will file a
copy of this TDS Agreement in accordance with Section 6(h) of the Settlement
Agreement with the United States Securities and Exchange Commission and other
similar or comparable governmental bodies, authorities or agencies, if necessary.

          (i) Jurisdiction. Subject to and without limiting Section 4.7 of the Patent License
Agreement, the Parties hereby irrevocably consent to the exclusive jurisdiction and venue of any
state or federal court sitting in the Commonwealth of Massachusetts, over any action or proceeding
arising out of or relating to this TDS Agreement or any agreement or document delivered in
connection herewith or therewith, and agree that all claims in respect of such action or proceeding
may be heard and determined in such state or federal court. Each of the Parties consents to the
jurisdiction of such court or courts for such actions or proceedings and agrees that the service
upon it of a summons and complaint by certified mail return receipt requested shall be sufficient
for such court or courts to exercise personal jurisdiction over the Parties for such actions or
proceedings. The Parties waive any objection to any action or proceeding relating to this TDS
Agreement in any state or federal court sitting in the Commonwealth of Massachusetts, on the basis
of forum non conveniens, lack of personal jurisdiction or otherwise.
Notwithstanding the foregoing, if any action or proceeding may not be brought in any
such court because all such courts lack subject matter jurisdiction, the Parties may bring such
action or proceeding in a court of appropriate jurisdiction.

          (j) Governing Law. This TDS Agreement shall be governed by, and construed and enforced
in accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to
its principles of conflicts of laws; provided that any dispute relating to the scope, validity,
enforceability, infringement or misuse of any Patent shall be governed by, and construed and
enforced in accordance with, the substantive laws of the jurisdiction in which such Patent
originates.

10

 

Trade Dress Settlement Agreement

          (k) Further Actions. Each Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this TDS Agreement.

          (l) Parties Advised by Counsel. This TDS Agreement has been negotiated between
unrelated Parties who are sophisticated and knowledgeable in the matters contained in this TDS
Agreement and who have acted in their own self interest. In addition, each Party has been
represented by legal counsel. This TDS Agreement shall not be interpreted or construed against any
Party to this TDS Agreement because that Party or any attorney or representative for that Party
drafted or participated in the drafting of this TDS Agreement.

          (m) Notices. All notices, demands, requests, approvals, consents or other
communications to be given or delivered under this TDS Agreement shall be in writing and shall be
deemed to have been given: (i) when delivered in person or by courier or confirmed facsimile; (ii)
upon confirmation of receipt when sent by certified mail, return receipt requested; or (iii) upon
receipt when sent by reputable private international courier with established tracking capability
(such as DHL, FedEx, or UPS), postage pre-paid, and addressed as set forth as the case may be, to
the noticed Party at the address set forth below, or such other address as a Party may specify by
written notice to the other.

          Notices shall be sent to Palomar at:

Palomar Medical Technologies
 82
Cambridge Street
 Burlington, MA
01803 
Attention: CEO

Facsimile: (781) 993-2377

          with a required copy to:

Palomar Medical Technologies
 82
Cambridge Street
 Burlington, MA
01803

Attention: General Counsel

Facsimile: (781) 993-2377

          and a further required copy to:

Goodwin Procter LLP
 Exchange
Place 
53 State Street
 Boston, MA
02109 
Attention: Kingsley Taft,
Esq. 
Facsimile: (617) 523-1231

11

 

Trade Dress Settlement Agreement

          and to Alma at:

Alma Lasers, Inc. 
485 Half
Day Road #100
 Buffalo
Grove, IL 60089
 Attention:
Howard Kelly
 Facsimile:
224-377-2050

          (n) Captions, Section Headings. As used in this TDS Agreement, “including” means
“including but not limited to”, and “herein”, “hereof”, and “hereunder” refer to this TDS Agreement
as a whole. The Section headings used herein are for reference and convenience only, and shall not
enter into the interpretation of this TDS Agreement. Unless otherwise expressly provided herein,
any reference to a number of “days” hereunder shall refer to calendar days. References to Sections
include subsections, which are part of the related Section (e.g., a section numbered “Section 4(a)”
would be part of “Section 4”, and references to “Section 4” would also refer to material contained
in the subsection described as “Section 4(a)”).

          (o) Mistakes of Fact or Law. Mistakes of fact or law shall not constitute grounds for
modification, avoidance or rescission of the terms of this TDS Agreement.

[remainder of this page intentionally left blank]

12

 

Trade Dress Settlement Agreement

     IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have each caused
its duly authorized representative to execute and deliver this TDS Agreement under seal as of the
Effective Date.

	 	 	 	 	 
	Palomar Medical Technologies, Inc.	 	 
	 
	 	 	 	 
	By:
	 	/s/ Joseph P. Caruso	 	 
	 

	 	

Name: Joseph P. Caruso
	 	 
	 

	 	Title: CEO	 	 
	 

	 	Date:	 	 
	 
	 	 	 	 
	Alma Lasers, Inc.	 	 
	 
	 	 	 	 
	By:
	 	/s/ Howard Kelly	 	 
	 

	 	 

Name: Howard Kelly
	 	 
	 

	 	Title: CEO	 	 
	 

	 	Date:	 	 
	 
	 	 	 	 
	Alma Lasers, Ltd.	 	 
	 
	 	 	 	 
	By:
	 	/s/ Howard Kelly	 	 
	 

	 	 

Name: Howard Kelly
	 	 
	 

	 	Title: CEO	 	 
	 

	 	Date:	 	 

 

 

Trade Dress Settlement Agreement

Exhibit A

Approved Trade Dress

Approved Trade Dress for the Harmony System and Aria System base unit/console:

Approved Trade Dress for the Harmony System and Aria System handpieces:

 

 

Trade Dress Settlement Agreement

Exhibit B

Existing Trade Dress

Harmony (examples from www.almalasers.com):

     

Aria (examples from www.almalasers.com):

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]